Evidence map›Paper›PMID 36858798›Full record

ArticleLife science alliance2023

RAS and PP2A activities converge on epigenetic gene regulation.

Anna Aakula, Mukund Sharma, Francesco Tabaro, Reetta Nätkin, Jesse Kamila, Henrik Honkanen, Matthieu Schapira, Cheryl Arrowsmith, Matti Nykter, Jukka Westermarck

Open access · goldAbstract read
In one paragraph

Article in Life science alliance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Post-translational modifications in CD8Frontiers in immunology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Anna AakulaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Mukund SharmaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID https://orcid.org/0000-0002-5816-8530
Francesco TabaroLaboratory of Computational Biology, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.
Reetta NätkinLaboratory of Computational Biology, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.ORCID https://orcid.org/0000-0001-7361-2057
Jesse KamilaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Henrik HonkanenTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Matthieu SchapiraStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Cheryl ArrowsmithStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Matti NykterLaboratory of Computational Biology, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.
Jukka WestermarckTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland jukwes@utu.fi.ORCID https://orcid.org/0000-0001-7478-3018
Åbo Akademi University · FITampere University · FIUniversity Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAS-mediated human cell transformation requires inhibition of the tumor suppressor protein phosphatase 2A (PP2A). However, the phosphoprotein targets and cellular processes in which RAS and PP2A activities converge in human cancers have not been systematically analyzed. Here, we discover that phosphosites co-regulated by RAS and PP2A are enriched on proteins involved in epigenetic gene regulation. As examples, RAS and PP2A co-regulate the same phosphorylation sites on HDAC1/2, KDM1A, MTA1/2, RNF168, and TP53BP1. We validate RAS- and PP2A-elicited regulation of HDAC1/2 chromatin recruitment, of RNF168-TP53BP1 interaction, and of gene expression. Consistent with their known synergistic effects in cancer, RAS activation and PP2A inhibition resulted in epigenetic reporter derepression and activation of oncogenic transcription. Transcriptional derepression by PP2A inhibition was associated with an increase in euchromatin and a decrease in global DNA methylation. Collectively, the results indicate that epigenetic protein complexes constitute a significant point of convergence for RAS hyperactivity and PP2A inhibition in cancer. Furthermore, the work provides an important resource for future studies focusing on phosphoregulation of epigenetic gene regulation in cancer and in other RAS/PP2A-regulated cellular processes.

Indexed as

DNA MethylationEpigenesis, GeneticGene Expression RegulationProtein Phosphatase 2ras ProteinsEpigenomicsHistone DemethylasesHumansPhosphoproteinsRepressor ProteinsTrans-ActivatorsUbiquitin-Protein LigasesHistone DemethylasesKDM1A protein, humanMTA1 protein, humanPhosphoproteinsProtein Phosphatase 2ras ProteinsRepressor ProteinsRNF168 protein, humanTrans-ActivatorsUbiquitin-Protein Ligases

Identifiers

PMID36858798
PMCPMC9979842
OpenAlexW4322757173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.